CD38 is a myeloma surface enzyme and the target of daratumumab, which is now given as a quick under-the-skin injection. This dossier gathers the 2 products (2 approved), 4 trials, 0 pathways and 0 resistance routes in the corpus that involve it, with external identifiers so it can be joined to UniProt, ChEMBL, Open Targets and the rest of biology.
Biology
CD38 is an ectoenzyme (NADase); immunomodulatory effects arise via depletion of CD38+ regulatory cells.
- Multiple myeloma
- AML (subset)
Elsewhere: identifiers and databases
Built from HGNC, Ensembl, UniProt and ChEMBL idsHow common it is, by cancer
Full matrix →| Cancer | Prevalence | Measure | Note | Source |
|---|---|---|---|---|
| Multiple myeloma | >95% | Plasma-cell surface expression | Wikipedia | |
| Acute myeloid leukaemia | 60-80% | Blast expression, variable intensity | Wikipedia |
Approximate, population-level figures; the measure column says what was counted. Ranges show the midpoint as a bar.
Products by modality and phase
Browse products →| Modality | Approved |
|---|---|
| Antibody 2 |
Trials
Evidence ranking →| Trial | Phase | Status | Setting | Result | Products |
|---|---|---|---|---|---|
| MajesTEC-3 NCT05083169 | 3 | Positive | Relapsed/refractory myeloma after 1-3 prior lines: teclistamab + daratumumab vs Dara-Pd or Dara-Vd | 36-month PFS 83.4% vs 29.7%; HR ~0.17. | |
| CEPHEUS NCT03652064 | 3 | Positive | Newly diagnosed transplant-ineligible or -deferred myeloma: Dara-VRd vs VRd | MRD-neg 60.9% vs 39.4%; PFS HR 0.57. | |
| IMROZ NCT03319667 | 3 | Positive | Newly diagnosed transplant-ineligible myeloma (age ≤80): Isa-VRd vs VRd | PFS HR 0.60. | |
| PERSEUS NCT03710603 | 3 | Positive | Newly diagnosed transplant-eligible myeloma: Dara-VRd induction/consolidation + DR maintenance vs VRd + R | PFS HR 0.42; 48-month PFS 84.3% vs 67.7%. |
Resistance routes that involve this target
Unaddressed routes →The resistance atlas has no route that names this target.
Pathways where it is a node
Pathway-to-drug matrix →No pathway diagram carries this target as a node.
Companion diagnostics and assays
Assay registry →No companion diagnostic in the registry measures this target.
Preclinical models
All models →No model entry for this target yet; check the cancer entries on the models page.
Open questions
All open questions →No open questions recorded for this target yet. Suggest one.
Ideas and companies
Key papers and the live literature
Preprints →- CEPHEUS: daratumumab quadruplet for newly diagnosed myeloma patients not having a transplant, with MRD-negativity as the main endpoint · Nature Medicine 2025
- PERSEUS: daratumumab added to bortezomib-lenalidomide-dexamethasone around autologous transplant in newly diagnosed myeloma · New England Journal of Medicine 2024
- MAIA: adding daratumumab to lenalidomide-dexamethasone for older patients with newly diagnosed myeloma who cannot have a transplant · New England Journal of Medicine 2019
Query for this target: (TITLE:"CD38" OR ABSTRACT:"CD38") AND (cancer OR tumor OR tumour OR oncology OR carcinoma OR lymphoma OR leukemia OR leukaemia OR myeloma OR sarcoma OR melanoma OR glioma). Results are unfiltered search hits about CD38, not a curated reading list.
Export
The dossier as machine-readable JSON: identifiers from HGNC, Ensembl, UniProt and ChEMBL, products with status, trials, pathways, hotspots, open questions and assays. The full entity record is in the open API at /api/v1/entities/cd38.json. Licence CC BY 4.0.